Atlas
Market PulseSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › DIVISLAB

DIVISLAB

Divi's Laboratories Limited
Large-capPharma ↗

What the six lenses say about DIVISLAB — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹6813.0
2026-07-10
VWAP · 1Y anchor
₹6380
+6.8% from VWAP
P/E · TTM
70.4×
TTM EPS ₹96.7
52-week range
87%
position low→high
RSI(14)
57
momentum

Own sector index

Pharma ↗
Overweight

1M

+6.2%

3M

+15.8%

1Y

+16.2%

Breadth >EMA21

72%

How DIVISLAB’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
8.0
avg conviction decile
Leadership
1/2
active lenses · Tech & Flow
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Large-cap cohortDRaw
TechnicalD1095›

The actual numbers

Price vs VWAP (1y)+6.8%
EMA trend stackUp · 21>50>200
Price vs 200-EMA+6.4%
Price vs 50-EMA+2.7%
RSI(14)57
RS vs Nifty 500 · 3M+8.1%
RS vs sector · 3M-4.4%
52-week range87%
Volume vs 30d avg0.62×
Volume vs 60d avg0.65×
ATR(14) · volatility157.7
Bollinger width · vol contraction0.054
FundamentalD870›

The actual numbers

Return on equity (ROE)16.5%
Return on capital (ROCE)22.0%
Operating margin32.3%
Net margin24.3%
Revenue growth · YoY+12.8%
EPS growth · YoY+17.2%
Debt / equity0.00×

Full 8-quarter history in the financials table below.

ValuationD10›

The actual numbers

P/E (TTM)70.4×
TTM EPS₹96.7
52-week range87%
CatalystD113›

The actual numbers

Earnings & momentum11
Capital actions5
Governance37

Every filing in the corporate-announcements panel below.

FlowD650›

The actual numbers

Promoter holding51.9%
Delivery · 30d avg58.7%
Up/down-day asymmetry2.6pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Large-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D10 + D6 ) ÷ 2 = 8.0(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Highest
91
Conviction score 91/100 · avg-decile strength 8.0/10
Conviction score91/100›
TechnicalD10›
FundamentalD8›
ValuationD1›
CatalystD1›
FlowD6›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-07-10.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+0.5pp
+2.8pp
-0.6pp
+11.8pp
+9.7pp
+5.0pp
Nifty 500
Broad-market baseline
+0.1pp
+2.7pp
-1.2pp
+8.1pp
+4.6pp
+1.2pp
Sector
Own-sector index
—
—
-3.6pp
-4.4pp
-9.8pp
-16.7pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

DIVISLAB daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
6813.00+58.00

Relative strength

RS vs baseline · rebased to 100

DIVISLAB ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
146.27+0.15

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)2,1182,3382,3192,5852,4102,7152,6042,831
↳ change QoQ—+10.4%-0.8%+11.5%-6.8%+12.7%-4.1%+8.7%
EBITDA (₹cr)701822825886729888890934
EBITDA margin33.1%35.2%35.6%34.3%30.3%32.7%34.2%33.0%
PAT (₹cr)430510589662545689583751
↳ change QoQ—+18.6%+15.5%+12.4%-17.7%+26.4%-15.4%+28.8%
Net margin20.3%21.8%25.4%25.6%22.6%25.4%22.4%26.5%
EPS (₹)16.2019.2022.2024.9420.5325.9521.9628.29
D/E————————
YoY growth · Mar '26Revenue +9.5% YoYPAT +13.4% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 11 Jun '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 29 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 25 May '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 23 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 23 May '26
    MEDIUMcapital
    Dividend
    ›

    A dividend declaration — a cash return to shareholders.

    View original filing on NSE ↗
  • 23 May '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 15 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 21 Mar '26
    LOWgovernance
    Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 14 Feb '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 11 Feb '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 11 Feb '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 3 Feb '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 14 Nov '25
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 12 Nov '25
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 7 Nov '25
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds DIVISLAB

Mutual funds holding DIVISLAB (10)

FundWeightAUM ₹crGrade
HDFC Flexi Cap Gr1.18%1,01,822
SBI Large Cap Reg Gr2.43%55,064
Nippon India Multi Cap Dir Bns0.80%54,585
Nippon India Multi Cap Bns0.80%54,585
Nippon India Multi Cap Gr0.80%54,585
Nippon India Large Cap Instl Bns1.06%53,227
Nippon India Large Cap Gr1.06%53,227
Nippon India Large Cap Dir Bns1.06%53,227
Nippon India Large Cap Bns1.06%53,227
SBI Large & Midcap Reg Gr1.34%40,850

ETFs holding DIVISLAB (10)

ETFWeightGrade
Nippon India Nifty Pharma ETF9.03%
Aditya BSL Nifty Healthcare ETF8.17%
DSP Nifty Healthcare ETF8.17%
Axis NIFTY Healthcare ETF8.17%
ICICI Pru Nifty Healthcare ETF7.68%
Mirae Asset Nifty 500 Healthcare ETF6.72%
Motilal Oswal BSE Healthcare ETF5.76%
ICICI Pru Nifty Next 50 ETF3.41%
UTI Nifty Next 50 ETF3.41%
F00000VIPU3.41%
Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma